What factors do you consider when deciding between dual vs single-agent immunotherapy for patients with MSI-H or dMMR metastatic CRC?

Given all the data we have, I am personally biased and prefer dual immunotherapy for most mCRC patients unless there is significant concern for tolerance (frail patients, limited disease burden, underlying well-controlled certain auto-immune disease, etc).

When making the decision between dual immune checkpoint, such as nivolumab/ipilimumab, versus monotherapy, I consider both available data as well as specific patient considerations. The first results from the nivolumab + ipilimumab versus nivolumab arms of the CheckMate 8HW trial were presented at G...